查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
單純皰疹病毒治療市場 - 2018-2028年全球行業規模、佔有率、趨勢、機會和預測，按病毒類型、治療方法、給藥途徑、配銷通路和地區分類
市場調查報告書
商品編碼
1303451

單純皰疹病毒治療市場 - 2018-2028年全球行業規模、佔有率、趨勢、機會和預測，按病毒類型、治療方法、給藥途徑、配銷通路和地區分類

Herpes Simplex Virus Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented by Virus Type, By Treatment, By Route of Administration, By Distribution Channel, By Region
出版日期: | 出版商: TechSci Research | 英文 113 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球單純皰疹病毒（HSV）治療市場預計將在預測期內見證令人矚目的成長。這可以歸因於人口老齡化的成長和單純皰疹感染和愛滋病毒等疾病病例的增加。此外，新興國家擴大使用不衛生的做法，以及對研究和開發活動的投資增加，都大幅增加了全球不同地區對單純皰疹病毒治療的需求。此外，對罕見病症有效治療的需求不斷成長，預計將進一步增加對單純皰疹病毒治療的需求，從而推動到2028年的市場成長。此外，人們對使用新療法優勢的認知不斷提高，加上全球各地對HSV治療的醫療支出不斷增加，預計在預測期內將進一步促進單純皰疹病毒治療市場。

HSV感染的流行率不斷提高

單純皰疹病毒感染患病率的增加，以及醫院獲得性感染率的增加和微生物的快速變異導致的新菌株，是在預測期內推動市場成長的主要因素。此外，在未發展和發展中地區，傳染病傳播的增加和清潔度的缺乏，在預測期內進一步推動了單純皰疹病毒感染治療市場。根據世界衛生組織的資料，感染HSV-2的女性多於男性。 2012年，估計有2.67億女性和1.5億男性感染了這種病毒。 HSV腦炎負擔的上升預計將推動這一領域的市場發展。此外，對藥物開發的關注度上升，對精準醫療的需求增加，以及家庭護理環境和照護端診斷的高度採用，對研發活動的投資增加，預計將在預測期內推動全球市場成長。

不斷成長的醫療保健支出

隨著技術創新、醫療保健支出的增加以及醫療保健設施和系統的改善，製藥和醫療保健部門迅速發展，這預計將在預測期內創造有利的成長。全球許多醫院、非住院手術護理中心和診所都採用先進的設備和器材，這將促進市場的成長。越來越多的計劃和研究機構之間的合作促進針對病毒的新型治療方案的開發，這預計將在預測期內促進市場成長。 2020年1月，來自瑞士洛桑EPFL、日內瓦大學（UNIGE）和曼徹斯特大學的科學家們透過研究合作，開發出了由糖製成的新型抗病毒材料，即殺病毒劑，顯示出治療單純皰疹（唇皰疹病毒）的前景。

可用的客製化

利用給定的市場資料，TechSci Research根據公司的具體需要提供客製化服務。本報告可提供以下客製化選項：

公司資訊

  • 其他市場參與者（最多5家）的詳細分析和概況。

目錄

第一章：產品概述

  • 市場定義
  • 市場範圍
    • 涵蓋的市場
    • 研究涵蓋的年份
    • 關鍵的市場細分

第二章：研究方法

  • 研究的目的
  • 基線方法
  • 主要行業合作夥伴
  • 主要協會和二級來源
  • 預測方法
  • 資料三角測量和驗證
  • 假設和限制

第三章：執行摘要

  • 市場概述
  • 主要市場細分概述
  • 主要市場參與者概述
  • 主要地區/國家概況
  • 市場驅動因素、挑戰、趨勢概述

第四章：客戶的聲音

第五章：臨床試驗分析

  • 進行的臨床試驗
  • 已完成的臨床試驗
  • 終止的臨床試驗
  • 按開發階段分類的管線細目
  • 按狀態分類的管線細目
  • 按研究應用分類的管線細目
  • 按地區分類的管線細目
  • 臨床試驗熱圖

第六章：全球單純皰疹病毒（HSV）治療市場展望

  • 市場規模和預測
    • 按價值
  • 市場佔有率與預測
    • 按病毒類型（HSV-1 v/s HSV-2）分類
    • 按治療方法（藥物 v/s 疫苗）分類
    • 按給藥途徑（口服、靜脈注射、外用）分類
    • 按銷售管道（醫院藥店、零售藥店、網路藥店）分類
    • 按地區
    • 按公司分類(2022年)
  • 市場地圖
    • 按病毒類型分類
    • 按治療方法分類
    • 按給藥途徑分類
    • 按銷售管道分類

第七章：北美單純皰疹病毒（HSV）治療市場展望

  • 市場規模和預測
    • 按價值分類
  • 市場佔有率和預測
    • 按病毒類型（HSV-1 v/s HSV-2）分類
    • 按治療方法（藥物 v/s 疫苗）分類
    • 按給藥途徑（口服、靜脈注射、外用）分類
    • 按銷售管道（醫院藥店、零售藥店、網路藥店）分類
    • 按國家分類
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

第八章：歐洲單純皰疹病毒（HSV）治療市場前景

  • 市場規模和預測
    • 按價值計算
  • 市場佔有率和預測
    • 按病毒類型（HSV-1 v/s HSV-2）分類
    • 按治療方法（藥物 v/s 疫苗）分類
    • 按給藥途徑（口服、靜脈注射、外用）分類
    • 按銷售管道（醫院藥店、零售藥店、網路藥店）分類
    • 按國家分類
  • 歐洲：國家分析
    • 法國
    • 德國
    • 英國
    • 義大利
    • 西班牙

第九章：亞太地區單純皰疹病毒（HSV）治療市場前景

  • 市場規模和預測
    • 按價值計算
  • 市場佔有率和預測
    • 按病毒類型（HSV-1 v/s HSV-2）分類
    • 按治療方法（藥物 v/s 疫苗）分類
    • 按給藥途徑（口服、靜脈注射、外用）分類
    • 按銷售管道（醫院藥店、零售藥店、網路藥店）分類
    • 按國家分類
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第十章：南美單純皰疹病毒（HSV）治療市場前景

  • 市場規模和預測
    • 按價值計算
  • 市場佔有率和預測
    • 按病毒類型（HSV-1 v/s HSV-2）分類
    • 按治療方法（藥物 v/s 疫苗）分類
    • 按給藥途徑（口服、靜脈注射、外用）分類
    • 按銷售管道（醫院藥店、零售藥店、網路藥店）分類
    • 按國家分類
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第11章：中東和非洲單純皰疹病毒（HSV）治療市場展望

  • 市場規模和預測
    • 按價值
  • 市場佔有率和預測
    • 按病毒類型（HSV-1 v/s HSV-2）分類
    • 按治療方法（藥物 v/s 疫苗）分類
    • 按給藥途徑（口服、靜脈注射、外用）分類
    • 按銷售管道（醫院藥店、零售藥店、網路藥店）分類
    • 按國家分類
  • MEA: 國家分析
    • 南非單純皰疹病毒（HSV）治療
    • 沙烏地阿拉伯單純皰疹病毒（HSV）治療
    • 阿拉伯聯合大公國單純皰疹病毒（HSV）治療

第十二章：市場動態

  • 驅動因素
  • 挑戰

第十三章：市場趨勢與發展

  • 最近的發展情況
  • 合併和收購
  • 產品發布

第十四章：競爭格局

  • 業務概況
  • 公司簡介
  • 產品與服務
  • 財務狀況（如報告所示）
  • 近期發展
  • SWOT分析
    • Novartis International AG
    • GlaxoSmithKline, plc.
    • Sanofi SA
    • Mylan NV
    • Emcure Pharmaceuticals Ltd.
    • Glenmark Pharmaceuticals Inc.
    • Fresenius Kabi AG
    • Apotex Inc.
    • Viatris Inc.
    • Teva Pharmaceuticals Industries Ltd

第十五章：戰略建議

簡介目錄
Product Code: 14594

Global Herpes Simplex Virus (HSV) Treatment Market is anticipated to witness impressive growth during the forecast period. This can be ascribed to the growing aging population and increased cases of diseases like Herpes Simplex infection and HIV. Additionally, the growing usage of unhygienic practices in emerging countries, along with rising investments in research and development activities, have significantly increased the demand for herpes simplex virus treatment across different parts of the globe. Moreover, the growing demand for efficient treatment for rare conditions is further expected to increase the demand for herpes simplex virus treatment, thereby fuelling market growth through 2028. Besides, growing awareness about the advantages of using new treatments, along with increasing healthcare expenditure on HSV treatment across the globe, is further expected to support the herpes simplex virus treatment market during the forecast period.

Increasing prevalence of HSV Infection

The increasing prevalence of Herpes Simplex Virus infection, along with the increasing rate of hospital-acquired infection and rapid mutations in the microorganism leading to new strains, are the major factors that will drive the growth of the market during the forecast period. Furthermore, the increasing transmission of infectious disease and lack of cleanliness in underdeveloped and developing regions are further propelling the herpes simplex virus infection treatment market during the forecast period. According to the World Health Organization, more women are infected with HSV-2 than men. In 2012, an estimated 267 million women and 150 million men were living with the infection. The rising burden of HSV encephalitis is expected to propel the market in this segment. As per the National Organization for Rare Disorders, the prevalence of acute encephalitis in the U.S. is around 2,000 cases per year, and it includes around 10% of total cases of encephalitis occurring in the U.S. Additionally, the rising focus on drug development, increasing demand for precision medicine along with high adoption of home care settings and point-of-care diagnostics, growing investments in research and development activities are expected to drive global market growth during the forecast period.

Growing Healthcare Expenditure

The pharma and healthcare sector are rapidly growing with technological innovations, increasing healthcare spending, and improving healthcare facilities and systems, which is expected to create lucrative growth during the forecast period. Many hospitals, ambulatory surgical care centers, and clinics are adopting advanced devices and equipment across the globe, which will enhance the growth of the market. Increasing initiatives and increasing collaborations between research organizations are facilitating the development of novel treatment alternatives against viruses, which is expected to boost market growth during the forecast period. In January 2020, a research collaboration between scientists from the EPFL in Lausanne, Switzerland, the University of Geneva (UNIGE), and the University of Manchester led to the development of novel antiviral materials, virucides, made from sugar that show promise for the treatment of herpes simplex (cold sore virus).

Market Segmentation

The global Herpes Simplex Virus (HSV) Treatment Market can be segmented by virus type, treatment, route of administration, distribution channel, and by region. Based on the virus type, the market can be divided into HSV-1 v/s HSV-2. Based on treatment, the market can be divided into Drugs v/s Vaccines. Based on the route of administration, the market can be differentiated into Oral, Intravenous, and Topical. Based on distribution channel, the market can be segmented into Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy. Regionally, North America dominated the market among Asia Pacific, Europe, Middle East & Africa, and South America. Among the different countries, the United States dominated the global herpes simplex virus treatment market on account of the growing demand for treatments due to the increasing prevalence of herpes simplex virus infection.

Market Players

Novartis International AG, GlaxoSmithKline, plc., Sanofi SA, Mylan N.V., Emcure Pharmaceuticals Ltd., Glenmark Pharmaceuticals Inc., Fresenius Kabi AG, Apotex Inc., Viatris Inc., Teva Pharmaceuticals Industries Ltd are some of the leading players operating in the Global Herpes Simplex Virus (HSV) Treatment Market.

Report Scope

In this report, Global Herpes Simplex Virus (HSV) Treatment systems market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:

Herpes Simplex Virus (HSV) Treatment Market, By Virus Type:

  • HSV-1
  • HSV-2

Herpes Simplex Virus (HSV) Treatment Market, By Treatment:

  • Drugs
    • Acyclovir
    • Valacyclovir
    • Famciclovir
    • Others
  • Vaccines
    • Simplirix
    • Others

Herpes Simplex Virus (HSV) Treatment Market, By Route of Administration:

  • Oral
  • Intravenous
  • Topical

Herpes Simplex Virus (HSV) Treatment Market, By Distribution Channel:

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Herpes Simplex Virus (HSV) Treatment Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • Germany
    • United Kingdom
    • Italy
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Australia
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in Global Herpes Simplex Virus (HSV) Treatment Market.

Available Customizations

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Clinical Trial Analysis

  • 5.1. Ongoing Clinical Trials
  • 5.2. Completed Clinical Trials
  • 5.3. Terminated Clinical Trials
  • 5.4. Breakdown of Pipeline, By Development Phase
  • 5.5. Breakdown of Pipeline, By Status
  • 5.6. Breakdown of Pipeline, By Study Application
  • 5.7. Breakdown of Pipeline, By Region
  • 5.8. Clinical Trials Heat Map

6. Global Herpes Simplex Virus (HSV) Treatment Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Virus Type (HSV-1 v/s HSV-2)
    • 6.2.2. By Treatment (Drugs v/s Vaccines)
      • 6.2.2.1. By Drugs (Acyclovir, Valacyclovir, Famciclovir, Others)
      • 6.2.2.2. By Vaccines (Simplirix, Others)
    • 6.2.3. By Route of Administration (Oral, Intravenous, Topical)
    • 6.2.4. By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)
    • 6.2.5. By Region
    • 6.2.6. By Company (2022)
  • 6.3. Market Map
    • 6.3.1. By Virus Type
    • 6.3.2. By Treatment
    • 6.3.3. By Route of Administration
    • 6.3.4. By Distribution Channel

7. North America Herpes Simplex Virus (HSV) Treatment Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Virus Type (HSV-1 v/s HSV-2)
    • 7.2.2. By Treatment (Drugs v/s Vaccines)
      • 7.2.2.1. By Drugs (Acyclovir, Valacyclovir, Famciclovir, Others)
      • 7.2.2.2. By Vaccines (Simplirix, Others)
    • 7.2.3. By Route of Administration (Oral, Intravenous, Topical)
    • 7.2.4. By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)
    • 7.2.5. By Country
  • 7.3. North America: Country Analysis
    • 7.3.1. United States Herpes Simplex Virus (HSV) Treatment Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Virus Type
        • 7.3.1.2.2. By Treatment
        • 7.3.1.2.3. By Route of Administration
        • 7.3.1.2.4. By Distribution Channel
    • 7.3.2. Canada Herpes Simplex Virus (HSV) Treatment Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Virus Type
        • 7.3.2.2.2. By Treatment
        • 7.3.2.2.3. By Route of Administration
        • 7.3.2.2.4. By Distribution Channel
    • 7.3.3. Mexico Herpes Simplex Virus (HSV) Treatment Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Virus Type
        • 7.3.3.2.2. By Treatment
        • 7.3.3.2.3. By Route of Administration
        • 7.3.3.2.4. By Distribution Channel

8. Europe Herpes Simplex Virus (HSV) Treatment Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Virus Type (HSV-1 v/s HSV-2)
    • 8.2.2. By Treatment (Drugs v/s Vaccines)
      • 8.2.2.1. By Drugs (Acyclovir, Valacyclovir, Famciclovir, Others)
      • 8.2.2.2. By Vaccines (Simplirix, Others)
    • 8.2.3. By Route of Administration (Oral, Intravenous, Topical)
    • 8.2.4. By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)
    • 8.2.5. By Country
  • 8.3. Europe: Country Analysis
    • 8.3.1. France Herpes Simplex Virus (HSV) Treatment Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Virus Type
        • 8.3.1.2.2. By Treatment
        • 8.3.1.2.3. By Route of Administration
        • 8.3.1.2.4. By Distribution Channel
    • 8.3.2. Germany Herpes Simplex Virus (HSV) Treatment Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Virus Type
        • 8.3.2.2.2. By Treatment
        • 8.3.2.2.3. By Route of Administration
        • 8.3.2.2.4. By Distribution Channel
    • 8.3.3. United Kingdom Herpes Simplex Virus (HSV) Treatment Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Virus Type
        • 8.3.3.2.2. By Treatment
        • 8.3.3.2.3. By Route of Administration
        • 8.3.3.2.4. By Distribution Channel
    • 8.3.4. Italy Herpes Simplex Virus (HSV) Treatment Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Virus Type
        • 8.3.4.2.2. By Treatment
        • 8.3.4.2.3. By Route of Administration
        • 8.3.4.2.4. By Distribution Channel
    • 8.3.5. Spain Herpes Simplex Virus (HSV) Treatment Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Virus Type
        • 8.3.5.2.2. By Treatment
        • 8.3.5.2.3. By Route of Administration
        • 8.3.5.2.4. By Distribution Channel

9. Asia-Pacific Herpes Simplex Virus (HSV) Treatment Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Virus Type (HSV-1 v/s HSV-2)
    • 9.2.2. By Treatment (Drugs v/s Vaccines)
      • 9.2.2.1. By Drugs (Acyclovir, Valacyclovir, Famciclovir, Others)
      • 9.2.2.2. By Vaccines (Simplirix, Others)
    • 9.2.3. By Route of Administration (Oral, Intravenous, Topical)
    • 9.2.4. By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)
    • 9.2.5. By Country
  • 9.3. Asia-Pacific: Country Analysis
    • 9.3.1. China Herpes Simplex Virus (HSV) Treatment Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Virus Type
        • 9.3.1.2.2. By Treatment
        • 9.3.1.2.3. By Route of Administration
        • 9.3.1.2.4. By Distribution Channel
    • 9.3.2. India Herpes Simplex Virus (HSV) Treatment Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Virus Type
        • 9.3.2.2.2. By Treatment
        • 9.3.2.2.3. By Route of Administration
        • 9.3.2.2.4. By Distribution Channel
    • 9.3.3. Japan Herpes Simplex Virus (HSV) Treatment Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Virus Type
        • 9.3.3.2.2. By Treatment
        • 9.3.3.2.3. By Route of Administration
        • 9.3.3.2.4. By Distribution Channel
    • 9.3.4. South Korea Herpes Simplex Virus (HSV) Treatment Market Outlook
      • 9.3.4.1. Market Size & Forecast
        • 9.3.4.1.1. By Value
      • 9.3.4.2. Market Share & Forecast
        • 9.3.4.2.1. By Virus Type
        • 9.3.4.2.2. By Treatment
        • 9.3.4.2.3. By Route of Administration
        • 9.3.4.2.4. By Distribution Channel
    • 9.3.5. Australia Herpes Simplex Virus (HSV) Treatment Market Outlook
      • 9.3.5.1. Market Size & Forecast
        • 9.3.5.1.1. By Value
      • 9.3.5.2. Market Share & Forecast
        • 9.3.5.2.1. By Virus Type
        • 9.3.5.2.2. By Treatment
        • 9.3.5.2.3. By Route of Administration
        • 9.3.5.2.4. By Distribution Channel

10. South America Herpes Simplex Virus (HSV) Treatment Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Virus Type (HSV-1 v/s HSV-2)
    • 10.2.2. By Treatment (Drugs v/s Vaccines)
      • 10.2.2.1. By Drugs (Acyclovir, Valacyclovir, Famciclovir, Others)
      • 10.2.2.2. By Vaccines (Simplirix, Others)
    • 10.2.3. By Route of Administration (Oral, Intravenous, Topical)
    • 10.2.4. By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)
    • 10.2.5. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Herpes Simplex Virus (HSV) Treatment Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Virus Type
        • 10.3.1.2.2. By Treatment
        • 10.3.1.2.3. By Route of Administration
        • 10.3.1.2.4. By Distribution Channel
    • 10.3.2. Argentina Herpes Simplex Virus (HSV) Treatment Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Virus Type
        • 10.3.2.2.2. By Treatment
        • 10.3.2.2.3. By Route of Administration
        • 10.3.2.2.4. By Distribution Channel
    • 10.3.3. Colombia Herpes Simplex Virus (HSV) Treatment Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Virus Type
        • 10.3.3.2.2. By Treatment
        • 10.3.3.2.3. By Route of Administration
        • 10.3.3.2.4. By Distribution Channel

11. Middle East and Africa Herpes Simplex Virus (HSV) Treatment Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value
  • 11.2. Market Share & Forecast
    • 11.2.1. By Virus Type (HSV-1 v/s HSV-2)
    • 11.2.2. By Treatment (Drugs v/s Vaccines)
      • 11.2.2.1. By Drugs (Acyclovir, Valacyclovir, Famciclovir, Others)
      • 11.2.2.2. By Vaccines (Simplirix, Others)
    • 11.2.3. By Route of Administration (Oral, Intravenous, Topical)
    • 11.2.4. By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)
    • 11.2.5. By Country
  • 11.3. MEA: Country Analysis
    • 11.3.1. South Africa Herpes Simplex Virus (HSV) Treatment Market Outlook
      • 11.3.1.1. Market Size & Forecast
        • 11.3.1.1.1. By Value
      • 11.3.1.2. Market Share & Forecast
        • 11.3.1.2.1. By Virus Type
        • 11.3.1.2.2. By Treatment
        • 11.3.1.2.3. By Route of Administration
        • 11.3.1.2.4. By Distribution Channel
    • 11.3.2. Saudi Arabia Herpes Simplex Virus (HSV) Treatment Market Outlook
      • 11.3.2.1. Market Size & Forecast
        • 11.3.2.1.1. By Value
      • 11.3.2.2. Market Share & Forecast
        • 11.3.2.2.1. By Virus Type
        • 11.3.2.2.2. By Treatment
        • 11.3.2.2.3. By Route of Administration
        • 11.3.2.2.4. By Distribution Channel
    • 11.3.3. UAE Herpes Simplex Virus (HSV) Treatment Market Outlook
      • 11.3.3.1. Market Size & Forecast
        • 11.3.3.1.1. By Value
      • 11.3.3.2. Market Share & Forecast
        • 11.3.3.2.1. By Virus Type
        • 11.3.3.2.2. By Treatment
        • 11.3.3.2.3. By Route of Administration
        • 11.3.3.2.4. By Distribution Channel

12. Market Dynamics

  • 12.1. Drivers
  • 12.2. Challenges

13. Market Trends & Developments

  • 13.1. Recent Developments
  • 13.2. Mergers & Acquisitions
  • 13.3. Product Launches

14. Competitive Landscape

  • 14.1. Business Overview
  • 14.2. Company Snapshot
  • 14.3. Products & Services
  • 14.4. Financials (As reported)
  • 14.5. Recent Developments
  • 14.6. SWOT Analysis
    • 14.6.1. Novartis International AG
    • 14.6.2. GlaxoSmithKline, plc.
    • 14.6.3. Sanofi SA
    • 14.6.4. Mylan N.V.
    • 14.6.5. Emcure Pharmaceuticals Ltd.
    • 14.6.6. Glenmark Pharmaceuticals Inc.
    • 14.6.7. Fresenius Kabi AG
    • 14.6.8. Apotex Inc.
    • 14.6.9. Viatris Inc.
    • 14.6.10. Teva Pharmaceuticals Industries Ltd

15. Strategic Recommendations